Recent developments include the company’s net loss report for FY26, plans to resubmit the NDA for GTx-104, completion of a $10 million private placement, and ongoing efforts to address FDA feedback following the CRL.

• Grace Therapeutics reported a net loss of $7 million for fiscal year 2026 and announced plans to resubmit the NDA for GTx-104 in subarachnoid hemorrhages [N1].
• The company reported steady progress and financials in early 2026, highlighting ongoing development activities [N2].
• In August 2026, Grace completed a $10 million private placement to support operations and regulatory efforts for GTx-104 [N1].
• The FDA issued a Complete Response Letter in April 2026 for GTx-104 citing manufacturing and non-clinical issues but no safety or efficacy concerns; the company is addressing these items [N1][S1].

The successful development and approval of GTx-104 could address significant limitations of oral nimodipine in aSAH patients, including improved delivery, reduced hypotension, and better patient outcomes. The orphan drug designation and potential exclusivity provide regulatory and commercial advantages. Positive Phase 3 trial results and favorable pharmacoeconomic data support the product’s value proposition. The company’s focused strategy on GTx-104 following strategic realignment concentrates resources on its lead candidate. Strong liquidity and recent capital raises support ongoing development and regulatory activities.

The FDA’s Complete Response Letter for GTx-104 highlights challenges in manufacturing and non-clinical data that must be resolved before approval. The company has incurred significant operating losses and has an accumulated deficit, indicating ongoing financial risk. Additional capital will be required to sustain operations and complete regulatory submissions, with no guarantee of successful approval or commercialization. The discontinuation of internal development for other pipeline candidates reduces diversification. The company operates in a highly regulated and competitive biopharmaceutical environment with inherent development and regulatory risks.

Grace Therapeutics’ moat is based on its proprietary drug delivery technologies and formulations, particularly the novel injectable formulation of nimodipine (GTx-104) that addresses significant unmet medical needs in aSAH treatment. The company holds an intellectual property portfolio with over 79 granted and pending patents worldwide. Its use of the FDA’s 505(b)(2) regulatory pathway leverages existing safety and efficacy data, potentially shortening development timelines. Orphan drug designation for its candidates provides potential market exclusivity and regulatory incentives. The clinical data from the Phase 3 STRIVE-ON trial supports the differentiated value proposition of GTx-104 compared to the current standard of care. However, the company remains dependent on successful regulatory approval and commercialization execution.

• Regulatory Approval Risk: The FDA issued a Complete Response Letter citing manufacturing and non-clinical data issues for GTx-104, requiring the company to address these before potential approval.
• Financial Risk: The company has incurred significant losses, with a net loss of $15.79 million in the latest quarter and an accumulated deficit of $244.27 million, necessitating additional capital raises.
• Pipeline Concentration Risk: Following strategic realignment, the company discontinued internal development funding for GTx-102 and GTx-101, focusing solely on GTx-104, reducing pipeline diversification.
• Operational Risk: The company’s ability to successfully resubmit the NDA, resolve FDA concerns, and commercialize GTx-104 depends on effective execution and sufficient resources.

• Grace Therapeutics, Inc. is focused on developing and commercializing products for rare and orphan diseases using novel drug delivery technologies, applying proprietary formulations to approved pharmaceutical compounds to improve efficacy, onset, side effects, and patient compliance.
• The company’s pipeline includes three unique clinical-stage drug candidates supported by over 79 granted and pending patents worldwide.
• The lead candidate, GTx-104, is a novel injectable formulation of nimodipine for intravenous infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients, designed to overcome limitations of oral nimodipine.
• GTx-104 uses nanoparticle technology to solubilize nimodipine for peripheral IV infusion, potentially eliminating nasogastric tube administration and reducing food effects, drug interactions, and dosing errors.
• GTx-104 has been administered to over 200 patients and healthy volunteers, showing good tolerability and lower pharmacokinetic variability compared to oral nimodipine.
• The company’s other candidates, GTx-102 and GTx-101, target ataxia-telangiectasia and postherpetic neuralgia respectively, but internal development funding for these was discontinued in June 2026.
• The company utilizes the FDA’s 505(b)(2) regulatory pathway leveraging existing safety and efficacy data to potentially shorten approval timelines.
• GTx-104 received orphan drug designation and may be eligible for orphan drug exclusivity, tax credits, and NDA fee waivers.
• The Phase 3 STRIVE-ON trial for GTx-104 met its primary endpoint, showing a 19% reduction in clinically significant hypotension episodes compared to oral nimodipine, with other clinical and pharmacoeconomic benefits.
• The FDA accepted the NDA for GTx-104 in August 2025 with a PDUFA target date of April 23, 2026, but issued a Complete Response Letter (CRL) in April 2026 citing CMC and non-clinical issues, not safety or efficacy.
• The company plans to resubmit the NDA addressing the FDA’s CRL comments and held a Type A meeting to clarify next steps.
• Grace Therapeutics reported a net loss of $15.79 million for the quarter ended June 30, 2026, with an EPS of -$0.91 per share.
• As of June 30, 2026, the company had $13.76 million in cash and cash equivalents and a current ratio of 11.47, indicating strong liquidity.
• The company completed a $10 million private placement in August 2026 to support operations and NDA resubmission efforts.
• The company’s accumulated deficit was $244.27 million as of June 30, 2026.
• The company implemented a strategic realignment in May 2023, focusing on GTx-104 development and reducing workforce and R&D activities for other candidates.
• The company’s management team includes experienced professionals in drug formulation, regulatory affairs, and commercialization, including a neurosurgeon-scientist expert in aSAH.